Xiao-Long Fu
Overview
Explore the profile of Xiao-Long Fu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Z, Zhou S, Zhang Q, Song Z, Liu W, Sun Y, et al.
Cell Res
. 2025 Feb;
PMID: 39966628
Equilibrioception (sensing of balance) is essential for mammals to perceive and navigate the three-dimensional world. A rapid mechanoelectrical transduction (MET) response in vestibular hair cells is crucial for detecting position...
2.
Zhang S, Zhang C, Hou R, Cai X, Liu J, Yu W, et al.
Clin Transl Radiat Oncol
. 2024 Dec;
50:100889.
PMID: 39634198
Background And Purpose: We aimed to assess the benefits of postoperative radiotherapy (PORT) in completely resected patients with pathologic stage IIIA(N2) non-small cell lung cancer (NSCLC) with a high risk...
3.
Tan X, Song X, Jiang M, Wang N, Liu J, Yu W, et al.
Transl Oncol
. 2024 Nov;
51:102195.
PMID: 39550889
Neoadjuvant therapy followed by surgery is a common clinical strategy for operable non-small cell lung cancer (NSCLC), and the mainstream neoadjuvant therapies include chemoimmunotherapy, targeted therapy, and chemotherapy. However, there...
4.
Xia W, Shen Y, Zhang C, Qian L, Wang H, Wang K, et al.
Transl Oncol
. 2024 Aug;
48:102074.
PMID: 39106551
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) respond poorly to immune checkpoint inhibitors (ICIs). It has been reported that the number of CD8T cells is reduced in EGFR-mutated NSCLC....
5.
Hu H, Xu X, Li X, Zeng Y, Li Y, Song X, et al.
Clin Transl Radiat Oncol
. 2024 Aug;
48:100818.
PMID: 39091465
Background: Chemotherapy plus immunotherapy has become the standard first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC), but median duration of response is only 7.0-8.3 months and progression-free...
6.
Jiang M, Qian L, Shen Y, Fu Y, Feng W, Ding Z, et al.
Neoplasia
. 2024 Feb;
50:100979.
PMID: 38387107
Background: Despite promising overall survival of stage I lung adenocarcinoma (LUAD) patients, 10-25 % of them still went through recurrence after surgery. [1] While it is still disputable whether adjuvant...
7.
Li Y, Lin L, Liu J, Cai X, Zhang Q, Song X, et al.
Future Oncol
. 2023 Nov;
19(34):2291-2296.
PMID: 37937444
This randomized phase II trial (NCT05978193) combines low-dose radiotherapy (LDRT) and conventionally fractionated radiotherapy (CFRT) with immunochemotherapy for metastatic esophageal squamous cell carcinoma, aiming to assess the potential enhanced effect...
8.
Song X, Liu J, Li H, Cai X, Li Z, Su Y, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686655
To develop accurate and accessible prediction methods for assessing pathologic response following NICT prior to surgery, we conducted a retrospective study including 137 patients with esophageal squamous cell carcinoma (ESCC)...
9.
Wang C, Zhao Y, Zhang Q, Zeng W, Jia T, Zhu L, et al.
Anticancer Drugs
. 2023 Feb;
34(7):852-856.
PMID: 36729892
The optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for...
10.
Zhang Y, Hu H, Zhou S, Xia W, Zhang Y, Zhang J, et al.
Biomark Res
. 2023 Jan;
11(1):10.
PMID: 36694213
Background: Cumulative preclinical and clinical evidences showed radiotherapy might augment systemic antitumoral responses to immunotherapy for metastatic non-small cell lung cancer, but the optimal timing of combination is still unclear....